Withdrawn × Neoplasm Metastasis × Gastrointestinal × Clear all Treat Primary and Metastatic Liver Tumors
Withdrawn
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
Phase 1 Withdrawn
Study of OB-002 in Patients With Refractory Metastatic Cancer
Phase 1 Withdrawn
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
Phase 2 Withdrawn
Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer
Phase 2 Withdrawn
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
Phase 2 Withdrawn
METRICS
Phase 3 Withdrawn
Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Phase 2 Withdrawn
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Phase 3 Withdrawn
LS301 Uptake in Tumors of Patients Undergoing Liver, Pancreas, or Gastric Surgery
Phase 1/2 Withdrawn
Anti-PD-1 +/- RT for MSI-H Solid Tumors
Phase 2 Withdrawn
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
Phase 1/2 Withdrawn
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction
Phase 1 Withdrawn
IRAM
Phase 2 Withdrawn
Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer
Phase 1 Withdrawn
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
Phase 1 Withdrawn
PanCAN
Phase 2 Withdrawn
A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
Phase 1 Withdrawn
RELIEF
Phase 1/2 Withdrawn
AUSCOR
Phase 2 Withdrawn
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
Phase 2 Withdrawn
Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases
Phase 2 Withdrawn
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
Phase 2 Withdrawn
Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment
Phase 2 Withdrawn
A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin
Phase 2 Withdrawn
Hepatic Artery Infusion With Oxaliplatin
Phase 1/2 Withdrawn
huC242-DM4 Treating Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
Phase 2 Withdrawn
KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer
Phase 1 Withdrawn
GENIUS
Phase 4 Withdrawn
OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas
Phase 1/2 Withdrawn
S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
Phase 2 Withdrawn
Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer
Phase 2 Withdrawn
FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer
Phase 2 Withdrawn
Magnetic Resonance Imaging (MRI) Using Liverspecific Oral Contrast Agent in Metastatic Colorectal Cancer Patients
Withdrawn
50 enrolled
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum
Phase 2 Withdrawn